Search Results for "Nortriptyline"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Nortriptyline. Results 1 to 10 of 10 total matches.
Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
nortriptyline amitriptyline fiber polyethylene glycol Miralax lubiprostone Amitiza Lotronex ...
View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1 doi:10.58347/tml.2025.1721c | Show Introduction Hide Introduction
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
(amitriptyline, desipramine, imipramine, and nortriptyline) ▶ Associated with jitteriness and convulsions ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721b | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for Abdominal Pain in Irritable Bowel Syndrome (IBS) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
, and constipation) ▪ Secondary amines (desipramine, nortriptyline) generally have fewer antihistaminic ...
View the Comparison Chart: Some Drugs for Abdominal Pain in Irritable Bowel Syndrome (IBS)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721d | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
▶ Amitriptyline is the only TCA
shown to be effective in clinical
trials
▶ Nortriptyline, which has fewer ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2 doi:10.58347/tml.2023.1678c | Show Introduction Hide Introduction
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
reuptake inhibitor (SNRI), or an antiseizure drug can
be used.
TCAs — Amitriptyline, nortriptyline ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023 (Issue 1691)
75 mg once/day 150 mg once/day 150.00
Nortriptyline – generic 10, 25, 50, 75 mg caps; 2 mg/mL soln ...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200 doi:10.58347/tml.2023.1691a | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
,
and weight gain. Other tricyclics such as nortriptyline,
which may have fewer adverse effects ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
, the tricyclic antidepressant nortriptyline
was more effective than an SSRI, but tricyclics can
cause cognitive ...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
) such as nortriptyline, doxepin,
and imipramine have been effective for treatment
of panic disorder and generalized ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
. Secondary
amines (desipramine and nortriptyline) generally have
fewer antihistaminic and anticholinergic ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction